These inhibitors improve the CD8+ cytotoxic T cell to regulatory T cell (CD4+FOXP3+) ratio, modulate cytokine levels (including IL-4, IFN-γ, and TNF-α), and enhance the tumor immune microenvironment [142]. The gene discussed is FOXP3; the disease is neoplasm.